Latest stories on KRSA
KRSA Initiated Coverage by Wells Fargo -- Rating Set to Overweight
GuruFocus63 · neutralanalyst
Wells Fargo initiates Korsana Biosciences stock at overweight, $44 target
Investing.com Analyst Ratings64 · neutralanalyst
Korsana Biosciences initiated with an Overweight at Wells Fargo
The Fly63 · neutralanalyst
Cyclerion Therapeutics GAAP EPS of -$3.19
Seeking Alpha34 · bearishearnings
Korsana Biosciences, Inc. (KRSA) files 8-K
SEC 8-K50 · neutralgeneral
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Business Insider58 · neutralearnings
Korsana Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire53 · neutralproduct/pr
Korsana Biosciences to Participate in Upcoming Investor Conferences
Business Insider53 · neutralproduct/pr
Korsana Biosciences initiated with a Buy at Guggenheim on KRSA-028 potential
The Fly61 · neutralanalyst
Wedbush initiates Korsana Biosciences stock with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
Wedbush starts Korsana at Outperform on Alzheimer’s potential
The Fly61 · neutralanalyst
Korsana Biosciences initiated with an Outperform at Wedbush
The Fly61 · neutralanalyst
Korsana Biosciences initiated with a Buy at Guggenheim
The Fly61 · neutralanalyst
Korsana Biosciences initiated with a Buy at TD Cowen
The Fly61 · neutralanalyst
Korsana Biosciences initiated with a Buy at Stifel
The Fly61 · neutralanalyst
Stifel initiates Korsana Biosciences stock with buy rating
Investing.com Analyst Ratings61 · neutralanalyst
Korsana Biosciences, Inc. (CYCN) files 8-K
SEC 8-K50 · neutralgeneral
UBS starts Korsana Biosciences at Buy on Alzheimer’s potential
The Fly61 · neutralanalyst
UBS initiates Korsana Biosciences stock with buy rating on Alzheimer’s drug potential
Investing.com Analyst Ratings61 · neutralanalyst
Korsana Biosciences initiated with a Buy at UBS
The Fly61 · neutralanalyst